Estrella Immunopharma Signals Commercial Shift With New CEO Cynthia Pussinen

EMERYVILLE, Calif. – October 26, 2026 – In the lifecycle of every successful clinical-stage biotechnology company, there arrives a critical inflection point: the moment when the scientific foundation must give way to the rigors of commercial manufacturing, regulatory strategy, and institutional capital formation. For Estrella Immunopharma (NASDAQ: ESLA), that moment has officially arrived.

Effective October 25, 2026, Cynthia Pussinen has taken the reins as Chief Executive Officer and Chairperson of the Board of Directors, succeeding founder Cheng Liu, Ph.D. Dr. Liu will pivot to the roles of Chief Scientific Officer and President, allowing him to focus on the underlying architecture of the company’s pipeline while Pussinen steers the corporate ship.

This executive reshuffle is a classic "Growth Signal." It indicates a company transitioning from a discovery-oriented mindset to an operational one. As Estrella advances its lead oncology candidate, EB103, into the dose-expansion phase of its Phase I/II trial, the appointment of a veteran with over three decades of biopharmaceutical leadership suggests the company is preparing for the grueling logistical realities of cellular therapy.

The Science of Safety: Challenging Conventional CAR-T

To understand the significance of Pussinen’s appointment, one must look at the clinical data driving Estrella’s momentum. The company is developing next-generation T-cell therapies utilizing the ARTEMIS platform, licensed from its parent company, Eureka Therapeutics.

The lead candidate, EB103, targets CD19—a well-validated protein found on the surface of most B-cell leukemias and lymphomas. However, unlike traditional Chimeric Antigen Receptor (CAR) T-cell therapies, which utilize synthetic receptors, the ARTEMIS platform is engineered to emulate endogenous T-cell receptor pathways.

The primary goal of this distinct mechanism is to decouple potent anti-tumor efficacy from the severe toxicities that have historically plagued the CAR-T landscape. In the initial dose-escalation cohorts of the STARLIGHT-1 Phase I/II clinical trial for relapsed or refractory B-cell non-Hodgkin's lymphoma, EB103 demonstrated complete responses with a highly notable safety profile: zero treatment-related serious adverse events.

If these safety signals hold through the dose-expansion phase, the implications are massive. Standard-of-care CD19 CAR-T therapies like Yescarta and Kymriah, while revolutionary, carry significant risks of Grade 3 or higher Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), affecting anywhere from 12% to 31% of patients in pivotal trials. A therapy that can deliver durable complete responses without triggering severe CRS or ICANS would not only reduce hospitalization costs but could significantly expand patient access in community oncology settings.

"Cynthia brings a rare combination of public-company leadership, hands-on experience in cell and gene therapy development and manufacturing, and a strong track record of building strategic and financial partnerships," said Dr. Liu in the company's announcement. "As Estrella enters its next phase of clinical development, the Board and I are confident that she is the right leader to build on the progress we have made."

A Commercial Veteran Takes the Helm

The cellular therapy sector is littered with brilliant science that failed on the manufacturing floor. Autologous T-cell therapy—where a patient's own cells are extracted, engineered, and reinfused—is as much a supply chain and logistics business as it is a biological one. This is exactly where Pussinen’s resume becomes Estrella’s strategic asset.

Pussinen joins Estrella from Sorbie Bornholm, where she managed biotech investments, but her operational chops were forged in the manufacturing trenches. As Chief Operating Officer at Sernova Corp., she led a corporate transformation spanning governance and operations. More tellingly, during her tenure as Global Head of Technical Operations at Spark Therapeutics (a member of the Roche Group), she spearheaded the manufacturing of advanced gene therapies. Her leadership there secured a $750 million capital investment from the Roche Board to build out gene therapy infrastructure.

"For early-stage cell therapy companies, the science gets you in the door, but manufacturing and logistics keep you in the building," noted one industry analyst focusing on advanced therapeutics. "Bringing in an executive who has managed three-quarter-of-a-billion-dollar infrastructure projects signals to the market that the company is serious about commercial viability, not just clinical endpoints."

In her own words, Pussinen recognizes the hurdles that remain in the space. "While CAR-T therapies have transformed the treatment landscape for certain cancers, significant unmet needs remain, particularly with respect to response durability, treatment-related toxicity and access for patients who may not be eligible for currently marketed therapies," she stated.

Navigating Capital and Parent Dynamics

Beyond trial execution and manufacturing scale-up, Pussinen faces the immediate challenge of capital formation. As a clinical-stage biotech listed on the NASDAQ, Estrella operates in a high-cash-burn environment. The dose-expansion phase of STARLIGHT-1 will require significant resources, as will the eventual preparation for pivotal trials.

Pussinen will also need to navigate the unique corporate structure of Estrella. As a spin-out from Eureka Therapeutics, Estrella relies on its parent company for its core ARTEMIS platform license. Managing this licensor-licensee relationship while independently courting institutional investors and forging new strategic partnerships will require a delicate touch. Her background in managing complex alliances and corporate turnarounds at companies like Ipsen Bioscience and Pfizer equips her well for this dual mandate.

Expanding the Horizon: Autoimmune and Beyond

Perhaps the most intriguing growth signal for Estrella is the potential application of the ARTEMIS platform beyond oncology. The broader biopharmaceutical industry is currently witnessing a massive pivot toward utilizing engineered T-cells for autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis.

Estrella is already developing EB104, a therapy that targets both CD19 and CD22, aimed at addressing relapses where tumors downregulate the CD19 antigen. The company has explicitly stated its intention to explore these therapies in autoimmune indications, where the demand for a safer, non-toxic T-cell therapy is even more pronounced than in late-stage oncology.

Patients with autoimmune diseases generally have longer life expectancies and lower tolerance for the severe toxicities associated with first-generation CAR-T therapies. If Estrella can prove that its ARTEMIS platform truly emulates endogenous pathways to eliminate severe CRS and ICANS, the company could find itself at the forefront of a multi-billion-dollar autoimmune market. Under Pussinen’s leadership, the roadmap from compelling early data to a scalable, commercial reality is now coming into sharper focus.